Capstone Therapeutics Corp., formerly known as OrthoLogic Corp., is a biotechnology company focused on developing a pipeline of novel therapeutic peptides aimed at helping patients with under-served medical conditions. The Company is engaged in the development and commercialization of two product platforms: AZX100 and Chrysalin. AZX100 is a novel synthetic 24-amino acid peptide, a class of compounds in the field of smooth muscle relaxation and fibrosis. AZX100 is currently being evaluated for commercially significant medical applications such as the treatment of pulmonary fibrosis, the prevention of hypertrophic and keloid scarring and intimal hyperplasia. Chrysalin, the Company's novel synthetic 23-amino acid peptide, stimulates cellular events leading to angiogenesis, revascularization, and repair of dermal and musculoskeletal tissues. It is currently being evaluated in disorders that involve vascular endothelial dysfunction. Capstone Therapeutics Corp. is headquartered in Tempe, Arizona.
Data provided by Zacks Investment Research or calculated by FXEmpire. All numbers are rounded to the closest decimal.
1 Total Shares outstanding is taken from the most recently filed quarterly or annual report.
2 Market Cap is calculated using total shares outstanding and the most recent share price.
3 EBITDA is calculated using methodology that may differ from that used by a company in its reporting.
4 The float is a measure of the number of shares available for trading by the public. It's calculated by taking the number of issued and outstanding shares minus any restricted stock, which might not be publicly traded.